BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211030
DTSTAMP:20260515T220448
CREATED:20210617T150512Z
LAST-MODIFIED:20210628T073150Z
UID:30590-1635206400-1635551999@www.pharmajournalist.com
SUMMARY:4th Targeted Protein Degradation Summit
DESCRIPTION:As the most comprehensive\, industry-focused and ‘must-attend’ event in the field\, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches\, perspectives\, and data-drive case studies that will continue to advance PROTACs\, molecular glues\, and other degrader modalities towards clinical success. \nWith 70+ world-class speakers and over 500 senior attendees from around the globe\, join the largest community of protein degradation experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to develop safe\, selective and effective PROTACs\, molecular glues\, lysosomal degradation\, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond. \nKey Highlights: \n\nEvaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics\, Arvinas\, Nurix Therapeutics & Bristol Myers Squibb\nDeep dive into the methodologies of enhancing target engagement by improving target specificity\, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly\, FogPharma\, GSK & Janssen\nReview the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers\, Parkinsons\, COVID-19 and AML with insights from Bristol Myers Squibb\, Progenra & Origami Therapeutics\nExplore the different approaches to penetrating the blood brain barrier\, comparing and contrasting the discovery\, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra\nOutline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee\, Ranok Therapeutics & Captor Therapeutics\n\nTo know more about 4th Targeted Protein Degradation Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-targeted-protein-degradation-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR